Genentech: Joshua Webster | Distinguished Scientist (Pathology-Collaborative), Pathology, Research Biology

Scientists / Our Scientists

"Pathologic evaluations can provide unique insights into the mechanisms of disease and the phenotypic consequences of molecular alterations that impact both basic discovery and drug development."

Years at Genentech

Publications at Genentech

Awards & Honors

While receiving my doctorate of veterinary medicine at Michigan State University, I became increasingly interested in understanding the pathogenesis and mechanisms of disease. This interest led me to complete a Ph.D. focused on the characterization of prognostic biomarkers for canine cutaneous mast cell tumors, a common, but clinically heterogeneous form of skin cancer in dogs. Following my Ph.D. I completed a residency in anatomic pathology at Purdue University and subsequently became boarded by the American College of Veterinary Pathologists. I then continued to pursue my interest in investigative pathology by accepting a position as a staff scientist in the Molecular Pathology Unit of the Laboratory of Cancer Biology and Genetics at the National Cancer Institute. In this position, I served as a collaborative pathologist where I incorporated both traditional interpretative light microscopy and image analysis-based quantitative analyses to support basic scientific research at the NCI. In 2012, I jumped at the opportunity to join the Research Pathology group at Genentech, where I support early discovery and Immunology programs, and oversee the microscopy and digital pathology core laboratories within Pathology.

Featured Publication

RIPK1 inhibits ZBP1-driven necroptosis during development.

Nature. 2016 Dec 1;540(7631):129-133.

Newton K, Wickliffe KE, Maltzman A, Dugger DL, Strasser A, Pham VC, Lill JR, Roose-Girma M, Warming S, Solon M, Ngu H, Webster JD, Dixit VM.

View Abstract

As a Research pathologist, I collaborate with cross-functional teams to provide all aspects of pathology support for a range of drug development activities from early discovery to biomarker development. A primary focus of my work at Genentech has been on the characterization of genetically engineered mouse models to understand molecular signaling and mechanisms of disease. This has been a rewarding opportunity to bridge molecular changes with their phenotypic consequences. I also provide pathologist oversight to the Center for Advanced Light Microscopy, the microscopy and digital pathology core facility, and the Electron Microscopy Laboratory in the Research Pathology.

Discovery of Clinical Candidate GDC-8264, a Novel, Potent and Selective RIP1 Inhibitor for Amelioration of Tissue Damage and the Treatment of Inflammatory Diseases

Journal of Medicinal Chemistry, ISSN: 00222623

Snahel D. Patel; Huifen Chen; Eugene E. Varfolomeev; Youngsu Kwon; Sreemathy Ramaswamy; Pawan Bir Kohli; John G. Quinn; Joshua D. Webster; Jialin Mao; Yuan Chen; Rina Fong; F. Esra Demircioglu; Patrick J. Lupardus; Craig E. Stivala; Gregory L. Hamilton; Michael Siu; Swathi Sujatha-Bhaskar; Vishnu Mohanan; Adeyemi O. Adedeji; Sara Francesca Santagostino; Jonathan M. Maher; Brent S. McKenzie; Michael Evan Rothenberg; Adam R. Johnson; Domagoj Vucic

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Joshua Webster

Distinguished Scientist (Pathology-Collaborative), Pathology, Research Biology

Featured Publication

RIPK1 inhibits ZBP1-driven necroptosis during development.